404 results on '"Galon J"'
Search Results
2. P1198: ASSOCIATION OF PRETREATMENT TUMOR CHARACTERISTICS AND CLINICAL OUTCOMES FOLLOWING SECOND-LINE AXICABTAGENE CILOLEUCEL VS STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
3. Glucocorticoid-Inducible Genes That Regulate T-Cell Function
4. Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study
5. Soluble FcγR, a biological perspective
6. Soluble CD16/FcγRIII Induces Maturation of Dendritic Cells and Production of Several Cytokines Including IL-12
7. 2237P Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial
8. 635P Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
9. Immune infiltration in human tumors: a prognostic factor that should not be ignored
10. SO-28 FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable mCRC patients: Updated and overall survival results of the phase II randomized AtezoTRIBE study
11. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer
12. 79O Clinical performance of Immunoscore® in early colon cancer in the Asian population
13. O-17 A TNM-Immune (TNM-I) classification staging system for predicting survival in colon cancer in a multicenter international SITC study
14. 79O Clinical performance of Immunoscore® in early colon cancer in the Asian population
15. 32P High levels of stromal tumour infiltrating lymphocytes, CD3, CD8 cells and Immunoscore® are associated with pathological CR and time to progression in TNBC patients undergoing neo-adjuvant chemotherapy
16. 491P Neoadjuvant nivolumab in early stage colorectal cancer
17. 1984P Tumour infiltrating lymphocytes in early breast cancer: High levels of CD3, CD8 cells and Immunoscore® are associated with pathological CR and time to progression in patients undergoing neo-adjuvant chemotherapy
18. Corrigendum to ‘Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study’
19. O-17 A TNM-Immune (TNM-I) classification staging system for predicting survival in colon cancer in a multicenter international SITC study
20. 46P Tumour infiltrating lymphocytes in breast cancer: High levels of CD3, CD8 cells and Immunoscore® are associated with pathological CR in patients receiving neo-adjuvant chemotherapy
21. Immunoscore predicts significant differences in time to recurrence in stage I colon cancer patients
22. A quantitative-PCR based method to estimate the fitness cost of antibiotic resistance in competition experiments: O346
23. Correction to: Toward a comprehensive view of cancer immune responsiveness: A synopsis from the SITC workshop (Journal for ImmunoTherapy of Cancer (2020) 7 (131) DOI: 10.1186/s40425-019-0602-4)
24. 336P Prognostic and predictive value of Immunoscore in stage III colorectal cancer in the combined SCOT and IDEA-HORG studies
25. Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)
26. High immunoscore is associated with good response to neo-adjuvant chemotherapy and prolonged survival in advanced head and neck cancer patients
27. The immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: Clinical significance for pathological response and survival
28. Significant differences in outcome between Immunoscore categories in stage I colon cancer patients
29. MSI status plus immunoscore to select metastatic colorectal cancer patients for immunotherapies
30. Hafnium Oxide Nanoparticle Activated By Radiation Therapy Generates an Anti-Tumor Immune Response
31. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
32. Preoperative nivolumab in patients(pts) with locally advanced colon cancer (T3 or T4): A window-of-opportunity study (NICOLE)
33. A novel post-surgical prognostic system for colorectal liver metastases treated by preoperative systemic treatment, using tumoral and non tumoral pathological changes, Ras mutation and immunoscore
34. Erratum: T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells (Cancer Cell (2016) 30(3) (377–390)(S1535610816303890)(10.1016/j.ccell.2016.08.004))
35. 78O - Immunoscore predicts significant differences in time to recurrence in stage I colon cancer patients
36. SP-0015: The impact of tumour infiltrating lymphocytes on clinical outcome after (chemo)radiotherapy
37. Caractérisation de l’évolution de la réponse immune dans la carcinogenèse bronchique épidermoïde
38. Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule
39. 1114PD - High immunoscore is associated with good response to neo-adjuvant chemotherapy and prolonged survival in advanced head and neck cancer patients
40. 937P - The immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: Clinical significance for pathological response and survival
41. 12P - MSI status plus immunoscore to select metastatic colorectal cancer patients for immunotherapies
42. Characterization of the immunoscore of synchronous resected primary tumor and liver colorectal cancer metastases
43. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015
44. 2154 Metastatic colorectal cancer has heterogeneous immune microenvironment and mutational expression
45. Future perspectives in melanoma research: meeting report from the 'Melanoma Bridge': Napoli, December 3rd-6th 2014
46. 610TiP - Preoperative nivolumab in patients(pts) with locally advanced colon cancer (T3 or T4): A window-of-opportunity study (NICOLE)
47. THU-155 - A novel post-surgical prognostic system for colorectal liver metastases treated by preoperative systemic treatment, using tumoral and non tumoral pathological changes, Ras mutation and immunoscore
48. Future perspectives in melanoma research. Meeting report from the ' Melanoma Bridge. Napoli, December 2nd-4th 2012'
49. Consensus guidelines for the detection of immunogenic cell death
50. 2154 Metastatic colorectal cancer has heterogeneous immune microenvironment and mutational expression
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.